When was Ausel founded?

Ausel was founded in 2021 and raised its 1st funding round 5 years after it was founded.

Where is Ausel located?

Ausel is headquartered in San Diego, United States.

Is Ausel a funded company?

Ausel is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Oct 22, 2026.

When was the latest funding round of Ausel?

Ausel's latest funding was a $***** Seed round on Oct 22, 2026, with participation from 0 investor.

Where does Ausel rank among its competitors?

Ausel ranks 208th amongst 152 active competitors, of which 47 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Ausel, which secured $120K in Oct, 2026.

Who are the top competitors of Ausel?

Ausel's top competitors include GRAIL, UDX and Exact Sciences. Among them, Ausel secured the most recent funding round in October, 2026.

Ausel - 2026 Company Profile, Funding & Competitors

Ausel is a seed company based in San Diego (United States), founded in 2021. It operates as a Developer of rapid non-invasive multi-cancer early detection medical tests. Ausel has raised $120K in funding. The company has 152 active competitors, including 47 funded and 23 that have exited. Its top competitors include companies like GRAIL, UDX and Exact Sciences.

Company Details

Developer of rapid non-invasive multi-cancer early detection medical tests. The company provides screening solutions designed to identify cancer at early stages to improve patient outcomes. Its technology focuses on advanced biomarker assessment to facilitate early intervention and long-term health monitoring. The organization operates from research facilities dedicated to refining diagnostic accuracy and accessibility for individuals seeking proactive health screenings.

Website: www.ausel.life/
Social

Key Metrics

Founded Year

2021

Location

San Diego, United States

Stage

Seed

Total Funding

$120K in 1 round

Latest Funding Round

Seed, Oct 22, 2026, $*****

Ranked

208^th among 208 competitors

Similar Companies

GRAIL & 206 more

View Ausel's full profile

Ausel has raised a total funding of $120K over 1 round.

Here is the list of recent funding rounds of Ausel:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 22, 2026	9573847	Seed	5414647	6955727	4803469	6044541

Access funding benchmarks and valuations. Sign up today!

View details of Ausel's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ausel include GRAIL, UDX and Exact Sciences. Here is the list of Top 10 competitors of Ausel, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	79/100
2nd	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	69/100
3rd	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	67/100
4th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
5th	Biocartis 2007, Mechelen (Belgium), Public	Manufacturer of automated molecular diagnostic systems for oncology biomarker testing	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	59/100
6th	Tethis 2004, Milan (Italy), Series A	Provider of automated solutions for in liquid biopsy	$15.3M	http://sanpaolope.com, Indaco Venture Partners ... & 5 others	56/100
7th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
8th	Biovica 2009, Uppsala (Sweden), Public	Drug response monitoring assay	$4.27M	EIC Fund, Europa	53/100
9th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
10th	Epigeneres 2008, Mumbai (India), Series B	Provider of genomics based diagnostic tests for cancer	$9.83M	Finessefabricrentals, Kotak Investment Advisors ... & 54 others	52/100
208th	Ausel 2021, San Diego (United States), Seed	Developer of rapid non-invasive multi-cancer early detection medical tests	$120K	-	-